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Various forms of distant healing (DH), including prayer and "psychic healing," are widely 
practiced, but insufficient formal research has been done to indicate whether such efforts actually 
affect health. We report on a double-blind randomized trial of DH in 40 patients with advanced 
AIDS. Subjects were pair-matched for CD4+ count and number of AIDS-defining illnesses 
and randomly selected to either 10 of DH treatment or a control group. DH treatment 
was performed by self-identified healers representing many different healing and spiritual 
traditions. Healers were located throughout the United States during the study, and subjects 
and healers never met. Subjects were assessed by psychometric testing and blood draw at enroll­
ment and followed for 6 months. At 6 months, a blind medical chart review found that treatment 
subjects acquired significantly fewer new AIDs-defining illnesses (0.1 versus 0.6 per patient P 
0.04), had lower illness severity (severity score 0.8 versus 2.65, P 0.03), and required signifi­
cantly fewer doctor visits (9.2 versus 13.0, P = 0.01), fewer hospitalizations (0.15 versus 0.6, P 
= 0.04), and fewer days of hospitalization (0.5 versus 3.4, P 0.04). Treated subjects also showed 
significantly improved mood compared with controls (Profile of Mood States score -26 versus 
14, P 0.02). There were no significant differences in CD4+ counts. These data support the 
possibility of a DH effect in AIDS and suggest the value of further research. 
Key to abbreviations used in text can be found on page 18 
KEYWORDS: Distant healing, AIDS, alternative medicine, complementary medicine, integra­
tive medicine, healing, prayer 
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D istant healing (DH) is defined as a conscious, dedicated act of mentation attempting to benefit another person's physical or emotional well-being at a distance. Various forms of DH, including prayer and 
some forms of spiritual healing, are widely reported and subscribed to the 
United States.2,3 Anecdotal experience with DH has stimulated a substantial 
body of research including at least 131 laboratory-published studies reviewed 
by Benor,4 of which 56 found significant effects Many of the studies, however, 
lacked rigorous control, measured only responses in vitro, involved only brief 
periods of influence, or did not include extended follow-up. The medical litera­
ture does contain a report of a rigorously controlled clinical study by Byrd5 
who investigated the of intercessory prayer for 383 patients sequentially 
admitted to the San Francisco General Hospital Coronary Care unit. The 
study reported a significant improvement in hospital course and decreased 
medical complications in the treated group, but the period of medical follow­
up was limited to the time each subject spent in the hospital, so delayed effects 
were not studied. In addition, outcome measures were not predefined. Thus, 
the longer-term efficacy of DH remains unstudied, and additional, scientifi­
cally rigorous studies are required to establish whether D H can be an effective 
intervention for life-threatening disease. 
For these reasons, and without having conducted any previous DH studies at 
all, we chose to evaluate DH in a population of advanced AIDS patients with 
6-month follow-up. Our initial study was a double-blind pilot study of 10 
treated and 10 control subjects conducted during July 1995 through January 
1996. The pilot study suggested both medical and psychological benefits of 
distant healing. Four of the 10 control group subjects died, with no deaths 
occurring in the treatment group, but the result was confounded by age (those 
who died were older). As a result, in the second larger study (reported here 
in full) a pair-matched design was used to control for factors shown to be 
associated with poorer prognosis in AIDS,6 specifically age, T cell count, and 
illness history. Additionally, an important intervening medical factor changed 
the endpoint in the study design. The pilot study was conducted before the 
introduction of "triple-drug therapy" (simultaneous use of a protease inhibitor 
and at least two antiretroviral drugs), which has been shown to have a signif­
icant effect on mortality? For the replication study (July 1996 through January 
1997, shortly after widespread introduction of triple-drug therapy in San 
Francisco), differences in mortality were not expected and different endpoints 
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were used in the study design. Based on results from the pilot study. we 
hypothesized that the DH treatment would be associated with: (1) improved 
disease progression (fewer and less severe AIDS-defining diseases [ADDs] and 
improved CD4+ level), (2) decreased medical utilization, and (3) improved 
psychological well-being. The results of this replication study are reported 
below. 
SUBJECTS AND METHODS 
F orty subjects were recruited by distributing flyers at clinics and at AIDS­related events and through advertisements in both gay and mainstream newspapers in the San Francisco Bay Area. Efforts were made to reach 
a wide range of socio-demographic populations. All subjects were requited to 
meet the criteria of the Centers for Disease Control AIDS category C-3 (CD4+ 
cell count <200 cells/fI1, history of at least one ADD)8 and to be talking 
Pneumocystis carinii pneumonia prophylaxis. Subjects signed informed consent, 
were photographed, and were randomly assigned on a double-blind basis the 
either DH or a control group. Subjects were told they had a 50-50 chance of 
receiving the DH treatment. Both groups continued to receive standard 
medical care at their primary care sites. Subjects were pair-matched by age, 
CD4+ count, and number of ADDs before randomization 
DATA ACQUISITION 
Subjects came to the laboratory or were visited at home to complete baseline 
and repeated measures at enrollment, at the end of the 10-week treatment 
intervention, and at follow-up 12-14 weeks later (Figure 1). Measurements 
taken were CD4+ count, psychological distress as measured by the Profile of 
Mood States (POMS),9 physical symptoms as measured by the Wahler Physical 
Symptom Inventory (WPSI),1O and quality of life as measured by the Medical 
Outcomes Survey (MOS) for HIV. l1 In addition, subjects reported doctor 
visits, hospitalizations, illness recovery, and onset of new illnesses. To verifY 
the report, 6 months from the start of the study a blind medical chart review 
was performed by a study physician who catalogued outpatient doctor visits, 
hospitalizations, and remission or development ofADDs over the study interval. 
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Figure 1. Study flow chart. 
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The review was done at 6 months only because of the focus of the study on 
extended treatment effects. Additional variables included subject's belief in the 
efficacy of DH, years HIV-positive, previous ADDs. protease inhibitor use, 
triple-drug therapy use, site of medical care delivery. use of complementary 
health practices, social support for study participation, drug and alcohol use, 
and demographics. Subjects were also asked, in a self-administered question­
naire, which group they thought they were in, treatment or controL For the 
one subject who died near the end of the study, all data were collected except 
the final CD4+ count 
EVALUATION OF ILLNESS SEVERIIT 
T o control for the variation in severity and prognosis of different AIDS­related illnesses, all illnesses were scored according to the Boston Health Study (BHS) Opportunistic Disease Score,12 which includes both 
AIDS-defining and secondary AIDS-related diseases. The BHS severity scoring 
system has been validated in predicting survival in two large populations of 
AIDS patients. New ADDs were counted as «ADDs acquired" only if blind 
chart review revealed no prior diagnosis of the condition; the only exception 
to this rule was Kaposi's sarcoma. Because cutaneous Kaposi's sarcoma is scored 
in a different severity category than visceral Kaposi's sarcoma, patients 
progressing from cutaneous to visceral Kaposi's sarcoma were counted as having 
acquired a new illness. Relapsing and remitting opportunistic diseases such as 
thrush or herpes or non-AIDS-defining bacterial infections were counted only 
once, whether or not there were recurrences. Recoveries from ADDs were 
tabulated when subjects' medical charts specifically stated a recovery had 
occurred or that there had been no evidence of the illness for at least 3 months. 
PAIR MATCHING 
Pair matching was done to control as much as possible for variation in outcomes 
that might be related to major disease progression and survival predictors, as 
indicated by the pilot study and in the medical literature.7,12 The variables 
were age, baseline CD4+ (T cell) count, and history of ADDs (sum of previous 
and current ADDs). These three variables were used to form matched subject 
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pairs. First, a normalized z score was computed for each subject for each 
variable by subtracting the mean for all subjects and dividing the result by the 
standard deviation for all subjects. Next, all pair-wise sums-of-squared differ­
ences in z scores between subjects (over the three variables) were computed. 
For each subject, an average difference from all the other subjects was 
calculated. Starting with the subject with the largest average difference, the 
closest match was found. The two matched subjects were eliminated from the 
list and the procedure was iterated until all 40 subjects were paired. A 
computer-generated binary random number was then used to randomly assign 
one member of each pair to treatment and one to control. 
BLINDING PROCEDURES 
All subject enrollment interviews were performed by one of two staff members who assigned subjects enrollment numbers. After enrollment was complete, a third staff member used a random number table to 
assign study code numbers to each of the enrollment numbers; these were 
substituted in the computer and used in randomization. Medical charts were 
obtained at the end of the study; names were removed from all text, and charts 
were assigned a new set of code numbers before they were reviewed. The 
chart reviewer did not know which subjects were in which group at the time 
of review. All data were entered into the computer by a research assistant who 
was blind to group assignment. Subjects learned their group assignment 1 
year after the study ended. 
TREATMENT PROCEDURES 
At the time of enrollment all subjects were photographed, and subject informa­
tion packets including 5 x 7-inch color photograph, first name, CD4+ count, 
and current symptoms were prepared by a research assistant. Ten copies of 
each packet were made and marked with removable labels indicating the 
subject's enrollment number. After randomization, the enrollment numbers 
were removed from the packets and replaced with the study codes. The packets 
were then divided into treatment and control groups based on the random­
ization results. Control subject packets were retained unopened in a locked 
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file drawer. Treatment subject packets were grouped in batches of five to be 
sent to each healer. Each of the five envelopes sent to the healers was marked 
with the day to be opened to begin the healing period for that patient. 
HEALERS 
Forty DH practitioners. including 12 from the pilot study, were recruited via 
professional healing associations and schools of healing. Eligibility criteria were 
minimum 5 years regular ongoing healing practice, previous healing experience 
at a distance with at least 10 patients, and previous healing experience with 
AIDS. 
Healers had an average of 17 years of experience and had previously treated an 
average of 106 patients at a distance. Practitioners included healers from 
Christian, Jewish, Buddhist, Native American, and shamanic traditions as well 
as graduates of secular schools of bioenergetic and meditative healing. 
Practitioners were not paid and understood that the study could not evaluate 
the abilities of any individual practitioner. Healers were residing at various 
locations throughout the United States. The site from which they performed 
their healing was not restricted. 
HEALING TREATMENT 
Arotating healing schedule randomized healers to subjects on a weekly basis to minimize possible differences in healer effectiveness. Thus, each subject in the DH group was treated by a total of 10 different 
practitioners, while each practitioner worked every other week treating a total 
of 5 subjects. Each healer received five consecutively numbered subject 
information packets with instructions specifying the day to begin treatment on 
each subject. Healers were asked to work on the assigned subject for approx­
imately 1 hour per day for 6 consecutive days with the instruction to "direct 
an intention for health and well-being" to the subject. Healers completed logs 
for each healing session, indicating period of healing. specific technique, and 
any impressions of the subject's illness. Subjects never met practitioners and 
did not know whether they were in the DH group, where the practitioners 
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were located, nor at what time the DH might occur. Before the intervention, 
study personnel encouraged and motivated healers via letters and phone calls 
stressing the importance of the study and their individual efforts. 
STATISTICAL METHODS 
Baseline and outcome comparisons between the two groups involved three statistical tests: paired t test for all continuous or multilevel variables, Wilcoxon signed-rank test when the data appeared to be 
skewed or contained outliers, and McNemar's test for 2 x 2 tables comparing 
paired binary variables. For study outcomes where P < 0.05, since many of 
the outcomes had skewed or clumped distributions (caused by tied values in 
outcome), a randomization test13 was also used to obtain an "exact" P value 
for the observed outcome. 
In addition, because study outcomes may be correlated, Hotelling's T-square 
statistic was used to determine whether there was a treatment effect on the 
array of 11 medical and psychological outcomes. Again. since this statistic 
assumes multivariate normality of the outcomes (which is not the case), statis­
tical significance of the outcome array was further assessed by conducting a 
randomization test on the T-square statistic. A randomization test is based on 
comparing a set of observed outcomes with those generated by randomly 
permuting the treatment-control assignment of subjects. Randomization tests 
are distribution free, that is, no assumption concerning the distribution of the 
test statistic is required. In this way, an unbiased determination of significance 
is obtained without assumptions concerning the distribution of the test statistic. 
(An informative discussion of randomization tests in a medical setting is 
contained in a recent issue of The American Statistician.) 14 This method for 
determining statistical significance was necessitated by the nature of the 
outcomes data. 
We also examined the effects of differences in base-line factors (those with two­
sided P < 0.2) on outcome variables by stratifYing on levels of baseline factor 
when they were discrete and by analysis of covariance when they were contin­
uous. 
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RESULTS 
BASELINE COMPARISONS 
Subjects were 37 men and 3 women with a mean age of 43 (Table I). Only 
one patient (DH group) had a history of intravenous drug use. There were 
no statistically significant differences on any baseline measures between the 
treated and control groups, including those used for pair-matching, or in 
ongoing AIDS management-related variables, such as use of triple-drug 
therapy (Table I). There were several near-significant differences (P < 0.20), 
however. All five baseline smokers and all four minorities were in the control 
group (P = 0.06 and P = 0.12, respectively). Of note, two treated subjects 
resumed their smoking habit during the study period (one near the beginning 
and one near the middle), reducing group smoking differences. The control 
group also was HIV-positive for a shorter time (7.3 versus 9.0 years, P = 0.11), 
showed a trend toward lower initial psychological distress scores (POMS 43 
versus 62, P = 0.19), and had used fewer alternative therapies (2.7 versus 4.2, 
P 0.10). 
Areview of primary care sites found no significant differences in site or type of medical practice (university, specialty clinic, solo practice). Review of charts, each containing complete medical history, found no 
major comorbid conditions (heart disease, cancer, diabetes) in either group. A 
majority of subjects (85%) expressed an a priori belief in the benefit of DH. 
The level of belief at baseline was nearly equal for both groups, and the belief 
showed no correlation with medical outcomes. 
MEDICAL AND PSYCHOSOCIAL OUTCOMES 
Over the 6-month study period, the D H group experienced significantly fewer 
outpatient doctor visits, fewer hospitalizations, fewer days of hospitalization. 
fewer new ADDs, and a significantly lower illness severity level as defined by 
the BHS scale (Table II). All diseases acquired are listed in Table III. At 6 
months, the DH group also showed significantly improved mood compared 
with controls as measured by the POMS, reflecting improvement on four of 
six subscales (depression, P < 0.02; tension, P < 0.02; confusion; P < 0.002; 
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Table I 
Baseline and AIDS Management-Related Variables 
Treated Control Two-sided 
pI20 20 
Age (Years 42.9 7.2 43.2 6.4 0.80 
Sex (% female subjects) 10 5 1.00 
Ethnic minority (% subjects) 0 20 0.12 
Education2 4.1 ± 0.6 3.9 ± 1.0 0.38 
Baseline AIDS-related factors 
Years HIV positive 9.0 ± 3,.5 7.3 ± 3.1 0.11 
CD4 cell number/ml 90.3 66.0 83.8 ± 70.9 0.55 
No. existing ADDS 1.4 1.3 1.3 ± 1.4 0.65 
No. prior ADDs 1.9 ± 1.3 2.1 ± 1.4 0.58 
ADD severirr 5.4 ± 3.0 5.0 ± 3.3 0.49 
Interventions during study 
Triple-drug therapy4 
Throughout study 70 80 0.72 
At least 2 months 20 15 1.00 
Protease inhibitors 90 95 1.00 
Pneumonia carinii prophylaxis 100 100 1.00 
No. alternative therapies5 4.2 ± 2.6 2.7 ± 2.0 0.10 
Support6 85 95 0.61 
Psychotherapy 45 50 1.00 
Baseline subjective measures 
WPSI score 1.64 ± 0.72 1.69 ± 0.80 0.86 
POMS score 62.3 ± 46.7 42.8 ± 39.9 0.16 
MOS score7 -0.01 0.8 -0.01 0.8 1.00 
Baseline personal habits 
Smokers 0 25 0.06 
Recreational drug uses 20 20 1.00 
Alcohol use9 0.4 ± 0.6 0.8 ± 1.1 0.27 
ExerciselO 1.4 ± 1.3 1.9 ± 1.4 0.34 
Meditation practice 60 75 0.50 
Religiousl spiritual practice 90 80 0.66 
Belief in DHII 2.8 ± 0.6 2.9 ± 0.4 0.33 
Data are means + SD or % 

IPaired t test for continuous variables, Wilcoxon signed-Rank test for variables with outliers, McNemar's test for 

binary variables; all tests are of matched paired differences. "Matched" refers to variables used for pair matching. 

2Some high school = 1, high school graduate = 2, some college = 3, college graduate = 4, graduate degree 5 

3Boston Health Study opportunistic disease score. 

4Simultaneous use of a protease inhibitor and at least two andretroviral drugs. 

5Acupuncture, psychic healing or prayer, Chinese herbs, yoga, biofeedback, guided imagery, Chi Gong, nutritional 

supplements or vitamins, special diet, therapy or other. 

6.Number of subjects reponing study support from family or communiry members. 

7Normalized mean for 10 factors. 





9No alcohol = 0, one or week = 1, several times a week = 2, heavily weekends = 3, daily 4. 

IONo exercise = 0, 
 1, twO or three = 2, four or times a week = 3, daily 4 
11"1 doubt it" = 0, 1, "Probably" = 2, = 3. 
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Table II 

Medical Course Over 6-Month Study 

Treated Control Two-tailed 
(n = 20) (n = 20) pI 
Outpatient visits 185 (9.2 ± 5.9) 260 (I 3.0 ± 7.0) 0.01 
Hospitalizations 3 (0.15 0.5) 12 (0.6 1.0) 0.04 
Days of hospitalization 10 (0.5 1.7) 68 (3.4 ± 6.2) 0.04 
Illness severity2 16 (0.80 ± 1.15) 43 (2.65 ± 2.41) 0.03 
ADDs acquired 2 (0.1 ± 0.3) 12 (0.6 ± 0.9) 0.04 
AD D recoveries 6 (0.3 ± 0.6) 2 (0.1 ± 0.3) 0.23 
CD4+ change (/)11)3 31.1 5.49 55.5 102.0 0.55 
Deaths o 1 1.00 
Change in POMS score (distress) -25.7 ± 46.0 14.2 ± 49.0 0.02 
Change in MOS 0.2 ± 0.8' -0.2 ± 0.8 0.15 
Change in WPSI -0.2 ± 0.6 0.1 ± 0.9 0.31 
Data are n (means + SO) or means + SO. 
IWilcoxon signed-rank test for the first seven outcomes; paired t tests for the last three outcomes; 
McNemar's test for number of deaths. Due to dumpiness of the data for variables near P = 
0.05, the randomization test was also performed with the following results: hospitalizations, P 
0.06; days of hospitalization, P 0.04; ADD severity score, P 0.03; ADDs acquired, P = 0.06. 
2Boston Health Survey opportunistic disease severity score, indudes ADD and AIDS-related illness 
(Table III). 
3n 19 in the control group (one subject died). 
fatigue, P < 0.02). Differences on the WPSI and MOS were not significant 
between groups. One death occurred in the control group, after the patient's 
follow-up questionnaire had been completed but 1 week before the 6-month 
study endpoint. There was a nonsignificant trend toward increase in CD4+ 
count for both groups, although the two groups did not differ significantly on 
this measure. Thus, the DH treatment was associated with significantly better 
outcomes on 6 of the 11 medical outcome measures. 
At study midpoint, immediately after the treatment intervention, subjects were 
asked if they thought they had been in the DH or control group. Two subjects 
(one from each group) did not respond. Nine of the DH group subjects and 
13 of the control group subjects believed they were in the DH group (P 
0.32; Fisher's exact test). Additional analysis was done to investigate possible 
correlation between subject belief about group assignment and study outcomes. 
Belief about group assignment did not correlate with any study outcome except 
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Table III 
Distribution of AIDS-Related Illnesses Acquired During the Study 
BHS severity group III (ADD) 
Kaposi's sarcoma (visceral) 
Mycobacterium avium complex 





Pneumocystic carinii pneumonia 
BHS severity group I (ADD) 
Esophageal candidiasis 
Kaposi's sarcoma (cutaneous) 
Recurrent pneumonia 







































blind medical chart review. 
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CD4+ change (P 0.05). This correlation no longer held when subjects were 
again asked to guess group assignment at the end of the 6-month study period 
(P = 0.28). At the end of the study period, subjects who had experienced 
more recoveries did tend to correctly guess they had been in the treatment 
group (P = 0.05). 
BASELINE EFFECTS ON OUTCOME 
Where baseline group differences were near-significant (P < 0,20), these variables were examined for correlation with all study outcomes. We found no effects of the baseline differences in 
smoking, number of years HIV-positive, or number of alternative therapies used 
on any outcomes. As described above, the treatment group tended to have 
higher baseline POMS scores (more distress) than controls. Higher baseline 
psychological distress, in both groups, was significantly correlated with greater 
reduction in psychological distress at the end of the study (P < 0.001). When 
baseline POMS was used as a covariate to adjust the POMS change scores, the 
difference in POMS change scores switched from statistical significance in favor 
of the treated to significance in favor of the controls. Baseline POMS values 
did not significantly correlate with any of the medical outcomes, although, as 
expected, they did correlate with the other psychological measures. 
Minority status (with all 4 minorities in the control group) showed a near­
significant difference at baseline. When this variable was examined within the 
control group (4 minorities versus 16 nonminorities), no significant correlation 
with study outcomes was found. However, a stratified analysis on all subjects, 
which takes minority differences in treatment-control pairs into account, 
resulted in a change in the P values from 0.04 to 0.09 for number of hospital 
stays and from 0.04 to 0.08 for number of hospital days. The difference in 
minority status among treated and control did not significantly correlate with 
any other outcome variable. 
ANALYSIS OF OUTCOME ARRAY 
Many of the outcomes in Table II are correlated with each other. Thus, it is 
useful to evaluate the treatment effect by using a statistic that takes into account 
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these correlations. The results of the randomization test applied to Hotelling's 
T-square statistic indicated that the array of all outcomes is statistically signif­
icant (P = 0.0154; that is, in the 10,000 random samplings only 154 T-squares 
exceeded the observed Hotelling T-square statistic). 
DISCUSSION 
T he findings of decreased medical utilization, fewer and less severe new illnesses, and improved mood for the treated group compared with the controls supports a positive therapeutic of DH. This outcome 
is difficult to explain, particularly in this double-blind study where subjects, 
physicians, and study personnel did not know who was in the treatment group. 
There are two explanations other than a DH that, in principle, could 
explain these data. 
First, differences between the group outcomes might be attributed to baseline 
medical or treatment differences, This possibility was not supported by 
univariate comparison of baseline AIDS-related variables, as shown in Table 1, 
where there were no statistically significant differences between the groups. 
Detailed analysis of baseline variables differing at P < 0.20 did find that higher 
base-line POMS scores were associated with greater improvement in POMS 
scores over the course of the study. By chance, patients in the treatment group 
showed more psychological distress at baseline, so their improved mood over 
the study interval may represent simply an effect of increased hope or expecta­
tion due to their participation in an intervention research study. The additional 
finding that adjusting for differences in baseline POMS caused a change in the 
direction of the beneficial effect is difficult to understand and is likely due to 
chance. 
While baseline psychological state, as measured by the POMS, did correlate 
with psychological outcomes, it did not correlate with any of the medical 
outcomes. Detailed examination of the effects of differences in baseline fac­
tors on outcomes also found a marginal effect of difference in minority status 
for hospitalizations This is an interesting finding but is weakened by the fact 
that in this study no minorities received DH. In fact, when hospitalizations 
and hospital days are examined within the control group alone, ethnicity does 
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not make a significant difference. Because our sample of minorities was so 
small and they all ended up in the control group, the fact that they had propor­
tionately more hospitalizations is very hard to interpret. Adjustment for their 
contributions has only a small effect on the P value, but clearly a larger sample 
with more minorities would be required to determine whether DH was affecting 
hospitalizations. It is important to point out that having conducted 50 statis­
tical tests to find interactions between differences in baseline factors and 
outcomes (excluding death), only two were found, which is the number 
expected by chance. We found no baseline differences with P < 0.20. which 
could explain differences in number of doctor visits or number or severity of 
new ADDs. Although there was a near-significant trend for more smokers in 
the control group, by the study midpoint treatment subjects who resumed 
smoking brought the distribution into better balance. There was no correla­
tion with smoking status and any study outcome. It does remain possible, 
however, that combinations of baseline variables or differences in some 
unmeasured variable may have influenced outcomes. 
A second possible explanation for the data is an expectation or placebo effect, as when patient improvement occurs due to a belief about the effectiveness of a treatment. 15,16 This is especially worth examining 
given the finding that baseline psychological status may have affected change 
in psychological well-being during this study. The expectation effect should 
lead to better outcomes among subjects who believe they were in the treatment 
group, regardless of their true group assignment. Differences in medical 
outcomes were related to true group assignment, however, and unrelated to 
assignment belief The only outcome measure showing correlation with subject 
belief was CD4+ count, and interestingly, this finding held up only at the study 
midpoint and not at the end of the study. Possibly, early in the study, subjects 
who believed they were in the treatment group came to this belief because they 
knew from some other source that their CD4+ count was rising. We cannot 
eliminate the possibility that hope or expectation as reflected by the subject's 
guess may have affected CD4+ count, but CD4+ count did not differ between 
the two study groups, so it does not seem likely this factor affected the differ­
ential study outcomes. 
The findings of reduction in medical utilization and development of fewer and 
less severe new illnesses suggest, as in the Byrd study, a global rather than a 
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specific D H effect. This study made an initial attempt to identify a specific 
marker of DH action by including CD4+ counts. Despite the differences in 
medical morbidity, however, there were no significant differences between the 
groups in CD4+ counts, which generally remained very low. Recent evidence 
suggests that viral load may be a better outcome predictor than CD4+ count. 17 
Future studies should seek specific markers of D H effect with viral load and 
natural killer cell activity 
Existing medical understanding offers no mechanism to account for a finding of healing at a distance; however, science does not require a known mechanism to prove the existence of a phenomenon. As pointed 
out by Dossey,18 for years no one knew how colchicine, morphine, aspirin, or 
quinine worked, yet they were known to be effective. Hand-washing, too, 
became standard medical practice well before a theory of infectious disease was 
described. Possible mechanisms for DH might include some form of mind­
to-mind communication between patient and practitioner or some form of 
previously undescribed energy transfer. Such concepts are, of course, highly 
speculative and remain an area for future research 
The finding of reduced medical utilization and improved medical course in the 
DH group is both exciting and surprising, but it remains crucial for this work 
to be replicated to be more confident that the effect is real. 
If the effect is robust future studies will also need to compare different D H 
techniques and investigate the efficacy of DH in different illnesses and with 
different subject populations. 
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ABBREVIATIONS USED IN TEXT 
ADD = AIDS-defining disease 
BHS = Boston Health Study 
DH Distant Healing 
MOS = Medical Outcomes Survey for HIV 
POMS = Profile of Mood States 
WPSI = Wahler Physical Symptom Inventory 
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